NCT06815250 Enhancing Maternal Vaccine Knowledge and Uptake: The InTroDuce-Programme Trial
| NCT ID | NCT06815250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universiti Putra Malaysia |
| Condition | Vaccination Uptake |
| Study Type | INTERVENTIONAL |
| Enrollment | 351 participants |
| Start Date | 2026-01-13 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 351 participants in total. It began in 2026-01-13 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this InTroDuce-Programme interventional trial aims to test whether a web-based educational program can improve pregnant women's knowledge about Influenza and Tdap vaccinations and increase their intention to get vaccinated in the future. The main questions it aims to answer are: Does the InTroDuce-Programme increase knowledge and future intention of pregnant mothers to get vaccinated against Influenza and Tdap? How does demographic factors, attitudes and barriers affect vaccination decisions among pregnant mothers? Researchers will compare InTroDuce-Programme to standard care (routine antenatal care) to see if InTroDuce-Programme works to improve knowledge and future intention of pregnant mothers to be vaccinated against Influenza and Tdap. Participants will: Receive the web-based educational module (InTroDuce-Programme), which covers the importance, safety, and effectiveness of vaccinations, as well as addressing common concerns. Be followed up one month after the intervention. Answer questionnaires before and after the intervention to measure changes in vaccination knowledge and future intention to get vaccinated
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged 18 years and older * Before or equal to 32 weeks of gestation as we need to follow-up the patients again at 36 weeks of gestation before delivery occurs. * Able to understand and consent to participation in the study. Exclusion Criteria: * Pregnant women with severe anaphylactic or allergic reactions to previous dose of influenza or Tdap vaccination. * Non-Malaysian
Contact & Investigator
Hung Chiun Lau, Dr Fam Med
PRINCIPAL INVESTIGATOR
Universiti Putra Malaysia
Frequently Asked Questions
Who can join the NCT06815250 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Vaccination Uptake. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06815250 currently recruiting?
Yes, NCT06815250 is actively recruiting participants. Contact the research team at hungchiun@upm.edu.my for enrollment information.
Where is the NCT06815250 trial being conducted?
This trial is being conducted at Bandar Baru Bangi, Malaysia, Cheras, Malaysia, Cheras, Malaysia, Kajang, Malaysia.
Who is sponsoring the NCT06815250 clinical trial?
NCT06815250 is sponsored by Universiti Putra Malaysia. The principal investigator is Hung Chiun Lau, Dr Fam Med at Universiti Putra Malaysia. The trial plans to enroll 351 participants.